Abstract
Alterations in glycosphingolipid (GSL) production results in lysosomal storage disorders associated with neurodegenerative changes. In Gaucher's disease, the patients also develop osteoporosis that is ameliorated upon treatment for the underlying defect in GSL metabolism. The role of GSLs in osteoclast and osteoblast formation is discussed here as well as the potential therapeutic uses of already approved drugs that limit GSL production in bone loss disorders such as multiple myeloma and periodontal disease.
Original language | English |
---|---|
Article number | 106 |
Pages (from-to) | 1-7 |
Journal | Frontiers in Endocrinology |
Volume | 3 |
DOIs | |
Publication status | Published - 23 Aug 2012 |